Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) shares were priced at $1.965 on 6 October 2026, down 3.20% on the day, and are down 24.13% over the past twelve months. The cell therapy company reported its financial results and operational update for the year ended 30 June 2026 on 26 and 27 August 2026, with figures in US dollars.

Across the broader market, the S&P/ASX 200 Health Care index [XHJ] (INDEXASX: XHJ) stood at 31,982.20, up 0.63% (+200.50 points) as of 6 October, and is down 16% over the past year. Meanwhile, the S&P/ASX 200 stood at 8,735.70, up 0.57% (+49.30 points) at the same time, and is down 2.74% over the year.

Business Model and Operational Footprint

Mesoblast develops allogeneic, or off-the-shelf, cellular medicines for severe and life-threatening inflammatory conditions, using its mesenchymal lineage cell therapy platform. Its lead product, Ryoncil (remestemcel-L-rknd), is approved by the US Food and Drug Administration for steroid-refractory acute graft versus host disease (SR-aGvHD) in paediatric patients aged two months and older, and is described as the first FDA-approved mesenchymal stromal cell therapy.

The company has locations in Australia, the United States and Singapore, with partnerships in Japan, Europe and China. A second platform, rexlemestrocel-L, is being developed for chronic low back pain and heart failure. The company reports more than 1,100 granted patents or Patent applications with protection extending to at least 2044 in major markets, and a proprietary Manufacturing process that yields cryopreserved, industrial-scale products.

Sector Dynamics

Cell and gene therapies operate in a regulated environment where approvals, payer coverage and site onboarding determine how quickly a product reaches patients. For Ryoncil, the company reported more than 50 transplant sites onboarded since launch, including 14 of the 15 largest paediatric sites, which account for nearly half of paediatric transplant volumes, and coverage of over 280 million lives across commercial and government payers.

Time to treatment is also tracked as an operating measure. The median time from patient identification to initiated treatment fell from 29 days at launch to 8 days. The company is pursuing label expansion to adults, a market it describes as three times the size of the paediatric segment, and a registrational trial in Duchenne muscular dystrophy.

FY26 Results Update

Total Revenue was $120.3 million, up from $17.2 million in the prior year. Ryoncil net revenue was $115.2 million after a gross-to-net adjustment of 13.4%. Reported Gross Profit was $103.6 million, and gross profit excluding Amortisation was $109.7 million against $16.0 million. Research and Development expense increased by $39.7 million after adjusting for a $23.0 million inventory benefit in the prior period, reflecting work on both platforms, Phase 3 trials and regulatory filings.

The reported net loss narrowed by 44%, or $44.6 million, to $57.5 million from $102.1 million. The second half net loss was $17.3 million, a 68% reduction on the prior comparable period. Net operating cash spend was $43.8 million, of which $13.4 million was in the second half, compared with $50.0 million a year earlier. Cash at period end was $103 million. During the year the company entered a $125.0 million five-year non-dilutive Credit Facility that consolidated and retired two higher cost facilities.

On the pipeline, the Phase 3 trial of rexlemestrocel-L in chronic low back pain completed treatment of 350 patients, increased from an original 300, with top-line results expected in mid-calendar 2027 after 12 months of follow-up. The company reported 76% Day 100 survival in adolescents and adults treated with Ryoncil as a third-line therapy in SR-aGvHD, compared with historical survival of 20% to 30%. The adult registration trial in combination with ruxolitinib is enrolling, with up to 40 US sites expected to be activated this year.

Growth Catalysts and Critical Operating Risks

The company lists several items it is advancing: adult SR-aGvHD label expansion as both a third-line treatment and part of a second-line regimen, the registrational trial in Duchenne muscular dystrophy following IND clearance, the Phase 3 low back pain read-out, a Biologics License Application filing number for rexlemestrocel-L in patients with a left ventricular assist device, and next-generation CAR-MSC and oncolytic virus-loaded MSC programs. It described chronic low back pain as affecting more than 7 million people in the United States and as a total addressable market above $10 billion.

Risks are set out in the release and in the company's filings. The Business remains loss-making, with a net loss of $57.5 million, and R&D spending increased during the year. Results of clinical trials, regulatory decisions, the timing of filings and modular review discussions with the FDA are uncertain. Commercial uptake depends on payer coverage, site adoption and market acceptance of stem-cell based therapies, and forward-looking statements note the potential for Withdrawal of products from the market due to adverse events.

The release also noted a webcast on the results, and cross-references the company's Form 20-F filed with the SEC and the Appendix 4E filed with the ASX for risk factors and management's discussion and analysis. Mesoblast's Chief Executive, Dr Silviu Itescu, said the company plans to extend Ryoncil to adult patients and described the back pain indication as a potential multi-billion-dollar market, statements that are forward-looking and subject to trial and regulatory outcomes.

The Bottom Line

Mesoblast's FY26 shows revenue of $120.3 million, up from $17.2 million, a narrower net loss of $57.5 million and cash of $103 million, while its shares are down 24.13% over the year and 3.20% on the day. The figures sit alongside a continuing net loss, higher R&D spending and several pending regulatory and clinical milestones, the nearest of which is the mid-2027 back pain trial read-out.